Anthony Kirck
Comptroller/Controller/Auditor bij OPTINOSE, INC.
Vermogen: 130 309 $ op 30-04-2024
Profiel
Anthony Kirck is currently the Chief Accounting Officer, VP & Controller at OptiNose, Inc. Prior to his current position, he worked as the Executive Director-Financial Planning & Analysis at Strongbridge Biopharma Plc from 2017 to 2020.
He also served as the Controller at Verrica Pharmaceuticals, Inc. from 2020 to 2021.
Mr. Kirck completed his undergraduate degree at Albright College.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
OPTINOSE, INC.
0.13% | 18-03-2024 | 143 988 ( 0.13% ) | 130 309 $ | 30-04-2024 |
Actieve functies van Anthony Kirck
| Bedrijven | Functie | Begin |
|---|---|---|
| OPTINOSE, INC. | Comptroller/Controller/Auditor | 01-11-2021 |
Eerdere bekende functies van Anthony Kirck
| Bedrijven | Functie | Einde |
|---|---|---|
| VERRICA PHARMACEUTICALS INC. | Comptroller/Controller/Auditor | 01-11-2021 |
| STRONGBRIDGE BIOPHARMA | Corporate Officer/Principal | 01-02-2020 |
Opleiding van Anthony Kirck
| Albright College | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| OPTINOSE, INC. | Health Technology |
| VERRICA PHARMACEUTICALS INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Strongbridge Biopharma Plc
 Strongbridge Biopharma Plc Pharmaceuticals: MajorHealth Technology Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA. | Health Technology |
